Physician profile
Mark T Witt
NPI 1881707875
$1,688.66
in general payments reported to CMS, 2019-2025
19 companies · $263 in 2025
The $263 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.61 · 2020: $102 · 2021: $307 · 2022: $391 · 2023: $288 · 2024: $294 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $360.13 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $255.08 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $243.71 | 2020-2024 | Jornay Pm |
| Pfizer INC. | $159.34 | 2019-2022 | |
| Sanofi Pasteur INC. | $130.61 | 2021-2025 | |
| Tris Pharma INC | $92.31 | 2020-2025 | Quillichew Er |
| Cranial Technologies, INC | $85.90 | 2021-2025 | Doc Band |
| Adlon Therapeutics L.P. | $55.22 | 2021 | |
| Supernus Pharmaceuticals, INC. | $52.10 | 2023-2024 | Qelbree, Qelbree |
| Sanofi-Aventis U.S. LLC | $45.39 | 2025 | |
| Seqirus USA INC | $42.73 | 2021-2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $37.06 | 2021-2023 | |
| Glaxosmithkline, LLC. | $35.62 | 2022 | |
| Sobi, INC | $20.50 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.31 | 2025 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $16.72 | 2023 | Moderna Covid-19 Vaccine |
| Genentech USA, INC. | $15.22 | 2020 | |
| Neurelis, INC. | $11.98 | 2021 | |
| Organon LLC | $10.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.